Esketamine/dexmedetomidine-based OFA markedly attenuates peri-operative IL-6 and NSE surges and is associated with a lower incidence of early POCD after TLH. These mechanistic findings warrant confirmation in a definitive randomized trial.
LI et al. (Wed,) studied this question.